Literature DB >> 7608212

Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity.

R Wienecke1, A König, J E DeClue.   

Abstract

Tuberous sclerosis (TSC) is a human genetic syndrome characterized by the development of benign tumors in a variety of tissues, as well as rare malignancies. Two different genetic loci have been implicated in TSC; one of these loci, the tuberous sclerosis-2 gene (TSC2), encodes an open reading frame with a putative protein product of 1784 amino acids. The putative TSC2 product (tuberin) contains a region of limited homology to the catalytic domain of Rap1GAP. We have generated antisera against the N-terminal and C-terminal portions of tuberin, and these antisera specifically recognize a 180-kDa protein in immunoprecipitation and immunoblotting analyses. A wide variety of human cell lines express the 180-kDa tuberin protein, and subcellular fractionation revealed that most tuberin is found in a membrane/particulate (100,000 x g) fraction. Immunoprecipitates of native tuberin contain an activity that specifically stimulates the intrinsic GTPase activity of Rap1a. These results were confirmed in assays with a C-terminal fragment of tuberin, expressed in bacteria or Sf9 cells. Tuberin did not stimulate the GTPase activity of Rap2, Ha-Ras, Rac, or Rho. These results suggest that the loss of tuberin leads to constitutive activation of Rap1 in tumors of patients with tuberous sclerosis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7608212     DOI: 10.1074/jbc.270.27.16409

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  Advances in the understanding of tuberous sclerosis.

Authors:  F J O'Callaghan; J P Osborne
Journal:  Arch Dis Child       Date:  2000-08       Impact factor: 3.791

Review 2.  Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms.

Authors:  S Johnson
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

3.  Mutational spectrum of the TSC1 gene in a cohort of 225 tuberous sclerosis complex patients: no evidence for genotype-phenotype correlation.

Authors:  M van Slegtenhorst; S Verhoef; A Tempelaars; L Bakker; Q Wang; M Wessels; R Bakker; M Nellist; D Lindhout; D Halley; A van den Ouweland
Journal:  J Med Genet       Date:  1999-04       Impact factor: 6.318

Review 4.  Nailing down a link between tuberin and renal cysts.

Authors:  David M Hockenbery
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

5.  Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling.

Authors:  Ken Inoki; Yong Li; Tian Xu; Kun-Liang Guan
Journal:  Genes Dev       Date:  2003-07-17       Impact factor: 11.361

6.  Reelin' in Genes for Cortical Dysplasia.

Authors:  Peter B. Crino
Journal:  Epilepsy Curr       Date:  2001-11       Impact factor: 7.500

7.  Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog.

Authors:  T Kobayashi; S Urakami; J P Cheadle; R Aspinwall; P Harris; J R Sampson; O Hino
Journal:  Mamm Genome       Date:  1997-08       Impact factor: 2.957

8.  Rap1 promotes multiple pancreatic islet cell functions and signals through mammalian target of rapamycin complex 1 to enhance proliferation.

Authors:  Patrick Kelly; Candice L Bailey; Patrick T Fueger; Christopher B Newgard; Patrick J Casey; Michelle E Kimple
Journal:  J Biol Chem       Date:  2010-03-25       Impact factor: 5.157

9.  Loss of function of the tuberous sclerosis 2 tumor suppressor gene results in embryonic lethality characterized by disrupted neuroepithelial growth and development.

Authors:  G Rennebeck; E V Kleymenova; R Anderson; R S Yeung; K Artzt; C L Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

10.  Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2.

Authors:  T Soucek; R S Yeung; M Hengstschläger
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.